Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00053677
Status:
COMPLETED
Last Update Posted:
2023-02-23
First Post:
2003-02-04
Brief Title:
Drug Treatment for Pathologic Gambling Disorder
Sponsor:
University of Chicago
Organization:
University of Chicago
Study Overview
Official Title:
Naltrexone Treatment in Pathologic Gambling Disorder
Status:
COMPLETED
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will establish the best dose of the drug naltrexone to treat patients with Pathological Gambling Disorder PGD and severe urge symptoms
Detailed Description:
PGD is a prominent and growing social problem Unfortunately there is no established drug treatment for this disorder Preliminary investigations demonstrate that naltrexone in doses up to 250 mgday is well tolerated and safe during an 11-week period and may be a viable treatment option for PGD patients with severe urges The implications of this study extend from PGD to other impulse control disorders including compulsive shopping kleptomania and possibly alcoholism
Participants are randomly assigned to receive either naltrexone or placebo for 16 weeks The responses of men and women are compared to determine whether efficacy is distributed in a malefemale ratio analogous to that of the PGD population in the United States A Clinical Global Impression and a Gambling Symptom Scale are used to assess participants
Participants are randomly assigned to receive either naltrexone or placebo for 16 weeks The responses of men and women are compared to determine whether efficacy is distributed in a malefemale ratio analogous to that of the PGD population in the United States A Clinical Global Impression and a Gambling Symptom Scale are used to assess participants
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DSIR AT-AS | US NIH GrantContract | None | httpsreporternihgovquickSearchR21MH065920 |
| R21MH065920 | NIH | None | None |